Hard-charg­ing GSK re­search chief Hal Bar­ron touts im­proved an­ti-BC­MA da­ta, aim­ing for fast ap­pli­ca­tions

Glax­o­SmithK­line R&D chief Hal Bar­ron tout­ed a fresh set of up­dat­ed da­ta on their an­ti-BC­MA an­ti­body drug con­ju­gate GSK2857916 on Thurs­day, point­ing to a sol­id 60% re­sponse rate from their DREAMM-1 study on mul­ti­ple myelo­ma as he bur­nished the phar­ma gi­ant’s im­proved late-stage prospects in on­col­o­gy.

Im­age: Hal Bar­ron. GSK

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER